{"id":"NCT00375427","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions","officialTitle":"A Prospective, Randomized, Multi-center Comparative 2-arm Trial of Efficacy and Safety of Zoledronic Acid (Every 3-months vs. Every 4 Weeks) Beyond Approximately 1 Year of Treatment With Zoledronic Acid in Patients With Bone Lesions From Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2010-02","completion":null,"firstPosted":"2006-09-13","resultsPosted":"2011-08-04","lastUpdate":"2012-04-11"},"enrollment":430,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer With Bone Metastasis"],"interventions":[{"type":"DRUG","name":"Zoledronic acid","otherNames":["ZOL446","ZometaÂ®"]}],"arms":[{"label":"Every 3 months","type":"EXPERIMENTAL"},{"label":"Every 4 weeks","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the clinical benefit of two different dosing schedules of zoledronic acid in patients with metastatic bone lesions from breast cancer who have already been treated with zoledronic acid for about one year.","primaryOutcome":{"measure":"Annual Overall Skeletal Morbidity Rate (SMR)","timeFrame":"12 months","effectByArm":[{"arm":"Zoledronic Acid Every 3 Months","deltaMin":0.26,"sd":0.81},{"arm":"Zoledronic Acid Every 4 Weeks","deltaMin":0.22,"sd":0.57}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":209},"commonTop":["Malignant neoplasm progression","Bone pain","Nausea","Asthenia","Pyrexia"]}}